These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 26901122)

  • 1. A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations.
    Van Hoeven N; Joshi SW; Nana GI; Bosco-Lauth A; Fox C; Bowen RA; Clements DE; Martyak T; Parks DE; Baldwin S; Reed SG; Coler RN
    PLoS One; 2016; 11(2):e0149610. PubMed ID: 26901122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection.
    Chu JH; Chiang CC; Ng ML
    J Immunol; 2007 Mar; 178(5):2699-705. PubMed ID: 17312111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice.
    Magnusson SE; Karlsson KH; Reimer JM; Corbach-Söhle S; Patel S; Richner JM; Nowotny N; Barzon L; Bengtsson KL; Ulbert S; Diamond MS; Stertman L
    Vaccine; 2014 Feb; 32(7):800-8. PubMed ID: 24380682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.
    McDonald WF; Huleatt JW; Foellmer HG; Hewitt D; Tang J; Desai P; Price A; Jacobs A; Takahashi VN; Huang Y; Nakaar V; Alexopoulou L; Fikrig E; Powell TJ
    J Infect Dis; 2007 Jun; 195(11):1607-17. PubMed ID: 17471430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.
    Schneeweiss A; Chabierski S; Salomo M; Delaroque N; Al-Robaiy S; Grunwald T; Bürki K; Liebert UG; Ulbert S
    Vaccine; 2011 Aug; 29(37):6352-7. PubMed ID: 21596075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supramolecular peptide hydrogel adjuvanted subunit vaccine elicits protective antibody responses against West Nile virus.
    Friedrich BM; Beasley DWC; Rudra JS
    Vaccine; 2016 Nov; 34(46):5479-5482. PubMed ID: 27670075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination of TLR-4 agonist and saponin adjuvants increases antibody diversity and protective efficacy of a recombinant West Nile Virus antigen.
    Van Hoeven N; Wiley S; Gage E; Fiore-Gartland A; Granger B; Gray S; Fox C; Clements DE; Parks DE; Winram S; Stinchcomb DT; Reed SG; Coler RN
    NPJ Vaccines; 2018; 3():39. PubMed ID: 30302281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens.
    Volz A; Lim S; Kaserer M; Lülf A; Marr L; Jany S; Deeg CA; Pijlman GP; Koraka P; Osterhaus AD; Martina BE; Sutter G
    Vaccine; 2016 Apr; 34(16):1915-26. PubMed ID: 26939903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys.
    Muraki Y; Fujita T; Matsuura M; Fuke I; Manabe S; Ishikawa T; Okuno Y; Morita K
    Virol J; 2015 Apr; 12():54. PubMed ID: 25889682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.
    Bonafé N; Rininger JA; Chubet RG; Foellmer HG; Fader S; Anderson JF; Bushmich SL; Anthony K; Ledizet M; Fikrig E; Koski RA; Kaplan P
    Vaccine; 2009 Jan; 27(2):213-22. PubMed ID: 18996430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys.
    Lieberman MM; Nerurkar VR; Luo H; Cropp B; Carrion R; de la Garza M; Coller BA; Clements D; Ogata S; Wong T; Martyak T; Weeks-Levy C
    Clin Vaccine Immunol; 2009 Sep; 16(9):1332-7. PubMed ID: 19641099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development.
    Throsby M; Ter Meulen J; Geuijen C; Goudsmit J; de Kruif J
    Expert Rev Vaccines; 2007 Apr; 6(2):183-91. PubMed ID: 17408368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of red-legged partridges (Alectoris rufa) against West Nile virus (WNV) infection after immunization with WNV recombinant envelope protein E (rE).
    Escribano-Romero E; Gamino V; Merino-Ramos T; Blázquez AB; Martín-Acebes MA; de Oya NJ; Gutiérrez-Guzmán AV; Escribano JM; Höfle U; Saiz JC
    Vaccine; 2013 Sep; 31(41):4523-7. PubMed ID: 23933372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses.
    Schepp-Berglind J; Luo M; Wang D; Wicker JA; Raja NU; Hoel BD; Holman DH; Barrett AD; Dong JY
    Clin Vaccine Immunol; 2007 Sep; 14(9):1117-26. PubMed ID: 17634508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.
    Spohn G; Jennings GT; Martina BE; Keller I; Beck M; Pumpens P; Osterhaus AD; Bachmann MF
    Virol J; 2010 Jul; 7():146. PubMed ID: 20604940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A recombinant fusion protein consisting of West Nile virus envelope domain III fused in-frame with equine CD40 ligand induces antiviral immune responses in horses.
    Liu SA; Haque M; Stanfield B; Andrews FM; Roy AA; Kousoulas KG
    Vet Microbiol; 2017 Jan; 198():51-58. PubMed ID: 28062007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination of captive nēnē (Branta sandvicensis) against West Nile virus using a protein-based vaccine (WN-80E).
    Jarvi SI; Hu D; Misajon K; Coller BA; Wong T; Lieberman MM
    J Wildl Dis; 2013 Jan; 49(1):152-6. PubMed ID: 23307381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model.
    Long MT; Gibbs EP; Mellencamp MW; Bowen RA; Seino KK; Zhang S; Beachboard SE; Humphrey PP
    Equine Vet J; 2007 Nov; 39(6):491-7. PubMed ID: 18065305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation and immunogenic properties of a recombinant West Nile subunit vaccine.
    Lieberman MM; Clements DE; Ogata S; Wang G; Corpuz G; Wong T; Martyak T; Gilson L; Coller BA; Leung J; Watts DM; Tesh RB; Siirin M; Travassos da Rosa A; Humphreys T; Weeks-Levy C
    Vaccine; 2007 Jan; 25(3):414-23. PubMed ID: 16996661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.